Jesus E. Juarez-Casillas

Radiation Oncology

5767 W Century Blvd
Suite 400
Los Angeles, CA 90045

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 12, 2025

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

Journal: PloS one

Published: August 29, 2025

Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.

Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.

Journal: European urology

Published: July 01, 2025

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy.

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy.

Journal: European urology oncology

Published: April 16, 2025

Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment.

Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment.

Journal: JNCI cancer spectrum

Published: March 11, 2025

Showing 1-5 of 5

Last Updated: 09/26/2026